Proving Target Relevancy: A Fast Path to Functional Biology with FFPE Proteomics

The majority of oncology therapies in development today are precision-guided, yet late-stage clinical failures remain common – largely stemming from insufficient human evidence to confirm an intended target is truly relevant in patients. To date, genomics measures provide limited insight into biology relevance, and to resolve this uncertainty and derisk development, teams need proof of mechanism: direct demonstration that the target is active and biologically consequential in the intended patient population. In this webinar, Sapient shares how next-generation FFPE proteomics can interrogate target relevancy through deep, direct measure of functional biology in FFPE tissue – leveraging the largest archives of outcomes-linked oncology samples to fast-track delivery of actionable human evidence.